Prenosis, a biology-based technology company delivering integrated diagnostics and therapeutics, announced today two major milestones: completion of its Series A Financing Round, and a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

Prenosis是一家基于生物学的技术公司，提供综合诊断和治疗方案，今天宣布了两个重要里程碑：完成了A轮融资，并与美国战略准备与响应管理局（ASPR）下属的生物医学高级研究与发展局（BARDA）签订了一份合同。

Department of Health and Human Services (HHS)..

卫生与公众服务部 (HHS)。

The $20 million financing round was led by PACE Healthcare Capital, with premier co-investors including UC Investments, UCI Health Ventures, the Labcorp Venture Fund, Global Health Investment Corporation (GHIC), Illinois Department of Commerce and Economic Opportunity (DCEO), and Carle Health. This financing will continue to support the commercial delivery of Prenosis' Sepsis ImmunoScore®, the first FDA-authorized AI diagnostic tool for sepsis..

这轮2000万美元的融资由PACE Healthcare Capital领投，主要共同投资者包括UC Investments、UCI Health Ventures、Labcorp Venture Fund、Global Health Investment Corporation (GHIC)、伊利诺伊州商务与经济机会部 (DCEO) 和 Carle Health。这笔资金将继续支持Prenosis公司Sepsis ImmunoScore®的商业化推广，这是首个获得FDA授权的脓毒症人工智能诊断工具。

Prenosis is a biology-based technology company redefining the standard of care for critical conditions. They believe healthcare should not follow a one-size-fits-all model. Instead, their mission is to tailor healthcare to each patient's biology through the creation and delivery of integrated diagnostics and therapeutics.

Prenosis是一家基于生物学的技术公司，致力于重新定义重症护理的标准。他们认为医疗保健不应遵循“一刀切”的模式，而是通过创建和提供综合诊断与治疗方法，根据每位患者的生物学特性来量身定制医疗服务。

Prenosis uses deep data and AI to build tools that augment clinical diagnosis of critical conditions based on each patient's unique biological profile. Unlike other AI-driven diagnostics, they go further by developing therapies that help providers deliver personalized care. Their Immunix™ platform powers the development of a variety of AI-based diagnostics, including Sepsis ImmunoScore®, the first FDA-authorized AI diagnostic tool for sepsis..

Prenosis利用深度数据和人工智能，构建基于每位患者独特生物特征的重症临床诊断工具。与其他人工智能驱动的诊断不同，他们更进一步开发了帮助医疗服务提供者实现个性化护理的疗法。其Immunix™平台推动了多种基于人工智能的诊断工具的开发，其中包括首款获得FDA批准的脓毒症人工智能诊断工具Sepsis ImmunoScore®。